Tuberc Respir Dis > Volume 71(4); 2011 > Article
Tuberculosis and Respiratory Diseases 2011;71(4):286-290.
DOI:    Published online October 1, 2011.
Successful Rechallenge with Gefitinib for an Initial Erlotinib-Responder with Advanced Lung Adenocarcinoma.
Sung Chul Hong, Yun Su Sim, Jin Hwa Lee, Yon Ju Ryu, Jung Hyun Chang
Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.
Although failure of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKI) is generally believed to be associated with cross-resistance to other EGFR TKI, the benefit of administering erlotinib as a second EGFR TKI after resistance of gefitinib as the first TKI has been well known. However, good response to gefitinib after an initial response to erlotinib has been rare. We report that a 45-year-old woman (never smoked), with lung adenocarcinoma and EGFR mutation, showed an initial response to erlotinib, and then responded to gefitinib again.
Key Words: erlotinib, gefitinib, Adenocarcinoma of lung

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail:                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next